SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at its first annual Research & Development Breakfast on Tuesday, October 24, 2006 at 7:30 a.m. ET at the Grand Hyatt Hotel in New York.
"Amylin's approach to discovering first-in-class medicines is yielding exciting results. At our first-ever Research and Development event, we will share our progress and plans," said Ginger L. Graham, Chief Executive Officer of Amylin Pharmaceuticals.
The presentation agenda for the R&D Breakfast includes: * Introduction/Corporate Overview Ginger L. Graham CEO, Amylin Pharmaceuticals * Clinical Development Orville Kolterman, MD Senior Vice President of Clinical and Regulatory Affairs, Amylin Pharmaceuticals * Early Development Alain Baron, MD Senior Vice President of Research, Amylin Pharmaceuticals * Discovery Research Michael Hanley, PhD Vice President of Discovery Research, Amylin Pharmaceuticals * Closing Remarks Daniel M. Bradbury President and Chief Operating Officer A question and answer session will follow the presentations.
The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at www.amylin.com. To access the live webcasts, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1250 employees nationwide. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
Amylin Pharmaceuticals, Inc.CONTACT: Alice Bahner, Executive Director, Investor Relations of AmylinPharmaceuticals, Inc., +1-858-552-2200, ext. 7272
Web site: http://www.amylin.com/
